Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects
This article was originally published in The Pink Sheet Daily
Executive Summary
Transcept's low-dose zolpidem for middle-of-the-night awakenings may need additional studies, including driving tests.
You may also be interested in...
Transcept Sees Road To Intermezzo Approval Without More Driving Studies
The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.
Transcept Sees Road To Intermezzo Approval Without More Driving Studies
The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.
Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data
FDA approved a resubmission plan that responds to concerns about inadvertent re-dosing and next-day driving impairment raised in an October "complete response" letter.